July 23, 2025 • By Research and Markets

The global insulated envelopes market was valued at $302.4 million in 2024 and is projected to reach $346.3 million by 2030, growing at a 2.3% CAGR. The market is driven by demand for cold chain packaging, perishable food delivery, and temperature-sensitive e-commerce shipments. Innovation in insulation and materials is enhancing product functionality, while end-use expansion in healthcare and food retail is increasing demand. The report analyzes the market, covering key segments and regions, and features 42 companies, including updates on global trade and economic shifts.

July 23, 2025 • By Adam Sarhan, Contributor, Adam Sarhan, Contributor https://www.forbes.com/sites/adamsarhan/

Alphabet, the parent company of Google, is set to report its earnings after Wednesday's close. The stock has been prone to big moves after reporting earnings and is currently trading near $190, 8.4% below its all-time high. The company is expected to report a gain of $2.15 per share on $79.14 billion in revenue, with the Whisper number being $2.21 per share. Alphabet's revenue is primarily driven by Google's advertising business, but YouTube and Google Cloud also contribute significantly. The company has made major advancements in artificial intelligence, cloud computing, and autonomous technologies. Investors will be watching how the market reacts to the earnings report, with the bulls hoping for a gap up and continued rally, and the bears hoping for a gap down and fall.

July 23, 2025 • By Haya Deeb, Suzanna Creasey, Diego Lucini de Ugarte, George Strevens, Trisha Usman, Hwee Yun Wong, Megan A. M. Kutzer, Emma Wilson, Tomasz Zieliński, Andrew J. Millar

Here is a concise summary of the news article: A study at the University of Edinburgh assessed the openness and FAIR (Findable, Accessible, Interoperable, and Reusable) aspects of data-sharing practices in biosciences research from 2014 to 2023. The study analyzed 555 research papers across four areas: biotechnology, regenerative medicine, infectious diseases, and non-communicable diseases. The results showed a progressive shift towards better data-sharing practices, with the fraction of publications sharing all relevant data increasing from 7% in 2014 to 45% in 2023. Data involving genomic sequences were shared more frequently than image data or human subject data. The presence of a data availability statement (DAS) or preprint sharing correlated with more and better data sharing. The study used a manual scoring system and the Open Data Detection in Publications (ODDPub) tool to evaluate data sharing practices. The findings highlight improvements in data sharing and advocate for continued advances in addressing challenges with data types and documentation.

July 23, 2025 • By Sage Lazzaro

Artificial intelligence (AI) is transforming the medical field, improving diagnosis, treatment, and patient care. A surgeon and dean of the Stanford School of Medicine, Lloyd B. Minor, tested ChatGPT's ability to provide information on a rare inner ear condition and found its response to be concise, accurate, and logical. AI is also enhancing drug discovery, allowing physicians to easily query databases and research potential treatment paths. Additionally, AI-powered patient care apps and wearables are supporting ongoing treatment for chronic conditions, increasing communication between physicians and patients. Overall, AI is revolutionizing the medical field, making it more efficient, accurate, and scalable.

July 23, 2025 • By Yiheng Ma, Liulu Yang, Yurong Yang

1. Introduction Toxoplasma gondii is an intracellular protozoan whose intermediate hosts span virtually all warm-blooded animals, including humans and non-human primates (NHPs). Felines are definiti…

July 23, 2025 • By Minmin Zhang, Yujie Shi, Xinyin Lu, Qiwei Zhang, Yubo Zhao, Shaohan Li, Zhiyuan Wen, Jinying Ge, Xijun Wang, Jie Li, Zhigao Bu, Xin Yin

Here is a concise summary of the news article in 8173 tokens or less: Researchers have made a significant discovery about the lumpy skin disease virus (LSDV), a member of the Poxviridae family that affects cattle. The study focused on the LSDV 001/156 gene, which is located in the inverted terminal repeat (ITR) region of the viral genome. The researchers found that the LSDV 001/156 gene plays a crucial role in viral replication and virulence by inhibiting the interferon (IFN) signaling pathway. Specifically, the gene product interacts with interferon regulatory factor 3 (IRF3), disrupting its dimerization and nuclear translocation, thereby attenuating IFN production. The study used homologous recombination to generate LSDV mutants with deletions of the LSDV 001/156 gene. The results showed that the mutant viruses had reduced replication and virulence in cattle compared to the wild-type virus. The researchers also found that the LSDV 001/156 gene is a late-expressed gene that is incorporated into virions and is involved in viral replication. The study provides new insights into the mechanisms underlying LSDV pathogenesis and highlights the importance of ITR-encoded genes in immune evasion and virulence. The findings also have implications for the development of effective control measures against LSDV and other poxvirus-related diseases. Overall, the study contributes to our understanding of viral pathogenesis and immune evasion strategies, and it sheds light on the critical role of the LSDV 001/156 gene in modulating the host intrinsic antiviral response.

July 23, 2025 • By Danilo Masoni

Global healthcare stocks are at their cheapest in decades, with a 20% discount to global equities, due to uncertainty over US drug pricing policies under the Trump administration. Despite this, fund inflows into the sector are increasing, with some investors looking past policy risks to long-term positive drivers such as aging populations and medical breakthroughs. However, a catalyst is needed to trigger a broad re-rating of the sector, which could come from interest rate cuts or clarity on drug pricing policies. Healthcare stocks have underperformed the S&P 500 by over 60 percentage points in the past three years, making it the worst sectoral performer on Wall Street.

July 23, 2025 • By Danilo Masoni

Global healthcare stocks are at their cheapest in decades, with the sector trading 11% below its long-term average and 20% below global equities. Despite this, investors remain cautious due to uncertainty over US drug pricing policies and potential tariffs on pharma imports. Some investors, however, are starting to look past the policy uncertainty and focus on long-term positive drivers such as aging populations and breakthroughs in new treatments. Fund inflows into the sector have picked up, with $7.2 billion in net inflows since the start of the year, but this is down 41% from last year. Investors are waiting for a catalyst to trigger a re-rating of the sector, which could come from interest rate cuts or clarity on US policy.

July 23, 2025 • By 247wallst.com

Here is a concise summary of the news article in 100 words or less: Insider buying has slowed down ahead of the new earnings-reporting season. However, notable purchases have been made in a couple of biotech companies, an e-commerce company, and a software maker. Despite the slow buying, some large purchases have been reported, indicating potential investment opportunities in these sectors.

July 23, 2025

Here is a concise summary of the news article in 8173 tokens or less: Researchers investigated the role of the SDR42E1 gene in vitamin D regulation and sterol metabolism. They used CRISPR/Cas9 gene-editing to introduce a nonsense variant of SDR42E1 into HCT116 colorectal cells, which led to significant dysregulation of sterol absorption and metabolism, as well as cancer-related signaling pathways. The study found that SDR42E1 deficiency reduced cell viability by 53% and altered the expression of key genes involved in vitamin D metabolism. The results suggest that SDR42E1 is a key modulator of vitamin D-related pathways and a potential therapeutic target for addressing vitamin D deficiency and associated pathologies, including cancer.

July 23, 2025 • By Research and Markets

A new report, "Bio/Pharmaceutical Outsourcing Report, May 2025", is available on ResearchAndMarkets.com. The report analyzes news and trends in pharmaceutical Contract Manufacturing Organizations (CMOs), including industry trends, contract service agreements, and value chain analysis. It covers topics such as US pharma manufacturing, regulatory trends, and company investments. The report also features updates on facility-level news, mergers, acquisitions, and financing among CMOs. Key companies and industry developments are highlighted, providing insights into the bio/pharmaceutical outsourcing market.

July 23, 2025 • By Tenvie Therapeutics, Inc.

Tenvie Therapeutics, a biotech company, has appointed Tony Estrada, Ph.D., as President and CEO, effective immediately. Dr. Estrada, a co-founder, previously served as President and Chief Scientific Officer. He brings 15 years of experience in drug development and small molecule therapeutics. The appointment reflects Tenvie's growth as it prepares to enter the clinic with its advanced programs, including an allosteric SARM1 inhibitor and an NLRP3 inhibitor. Dr. Estrada will drive the company's strategic leadership and business operations, aiming to achieve key clinical milestones. Tenvie is focused on developing small molecules to treat neurological diseases, with a pipeline targeting critical neurological pathways.

July 23, 2025 • By Noor Lobad

HeatBounce uses a proprietary molecular shield called ResiliCore to protect and condition hair strands.

July 23, 2025 • By Phoebe Liu, Forbes Staff, Phoebe Liu, Forbes Staff https://www.forbes.com/sites/phoebeliu/

Here is a concise summary of the news article: Christina Cacioppo's software startup, Vanta, has raised $150 million in new funding, valuing the company at $4.15 billion. Despite not needing the money, Cacioppo decided to take the funding to capitalize on market opportunities and execute the company's long-term goals. Vanta, a security and compliance software company, has grown to over 1,000 employees and $220 million in annual recurring revenue. The company plans to expand into government partnerships, invest in AI, and make acquisitions. Cacioppo's goal is to make Vanta an "enduring sustainable company" and potentially take it public in the future.

July 23, 2025 • By Morgan Phillips

Here is a concise summary of the news article: AI investor Arnie Bellini predicts that future battles will be fought by robots, with the US and China racing to integrate artificial intelligence into their war machines. The US is responding with a $36 billion modernization initiative, including AI-assisted command-and-control and autonomous systems. Bellini believes that US cyber espionage and AI could prevent a war with China before it starts. The US military is also exploring AI-driven biotech, including gene-edited soldiers, while China is pushing the envelope further. Experts warn that China may not prioritize human oversight in lethal AI decisions, highlighting the need for protocols aligned with American values. As AI redefines warfare, the battlefield may be measured in algorithms, networks, and gene sequences rather than traditional arms.

July 23, 2025 • By Dahvi Shira, Contributor, Dahvi Shira, Contributor https://www.forbes.com/sites/dahvishira/

K18, a biomimetic hair brand, is launching HeatBounce, a conditioning heat protectant that uses proprietary ResiliCore heat-shielding technology. This technology is inspired by nature's most flexible and heat-resilient protein, resilin, and is designed to dynamically activate with heat to reinforce the inner structure of the hair fiber. HeatBounce is lightweight, breathable, and provides protection from within, unlike traditional rubberized approaches. It can be used on damp or dry hair before heat styling and can also double as a daily shield. The product is set to launch in a week and has a current waitlist. K18 co-founder Suveen Sahib emphasizes that HeatBounce is a game-changer in the heat protection category, which has remained stagnant for decades. The brand will educate consumers about HeatBounce through its ambassador Devante Turnbull and will continue to focus on its pillars of biology-driven, molecular formulations.

July 23, 2025 • By 7news

The University of Queensland's revolutionary Molecular Clamp technology has been acquired by pharmaceutical giant Sanofi in a billion-dollar deal. The technology, which promises to fast-track vaccine development against future pandemics, has been licensed to Vicebio, a biotech company that will be purchased by Sanofi for up to $US1.6 billion. The acquisition includes an immediate $US1.15 billion payment and potential milestone payments of $US450 million. The technology has the potential to protect older adults against multiple respiratory viruses with a single immunization. The University of Queensland's Vice-Chancellor, Professor Deborah Terry, described the acquisition as "extraordinary validation of Australian research excellence." The deal highlights the strength of Australia's innovation ecosystem and world-class research emerging from its universities.